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Pyruvate kinase (PK) deficiency is the most common cause of heredi-
tary non-spherocytic hemolytic anemia and is characterized by consid-
erable genotypic heterogeneity, with over 350 documented
pathogenic mutations in the PKLR gene.1,2 Clinical manifestations range
from a mild, asymptomatic well-compensated anemia to a severe
transfusion-dependent hemolytic anemia from birth.3,4 Other complica-
tions of PK deficiency include iron overload, pulmonary hypertension,
endocrinopathies, liver failure, biliary disease, and extramedullary
hematopoiesis, among others.3,4 Splenectomy, a common supportive
treatment, may partially ameliorate the anemia and reduce transfusion
requirements.5 Hemoglobin concentrations correlate poorly with
symptoms in PK deficiency6; therefore, transfusion requirements are
typically used to classify disease severity, with those who are regularly
transfused (often labeled “transfusion-dependent”) despite splenec-
tomy assumed to be the most severely-affected subgroup. Our under-
standing of the clinical characteristics of this most severe subgroup is
quite limited. Therefore, in this study, we aimed to describe the differ-
ences in clinical characteristics and disease complications between reg-
ularly transfused splenectomized patients with PK deficiency, and
those who were also splenectomized but did not require regular trans-
fusions. As is observed in other hereditary hemolytic anemias,
we hypothesized that patients with pyruvate kinase deficiency requir-
ing regular transfusions would have higher rates of disease
complications.
Using data collected from the Pyruvate Kinase Deficiency Natural
History Study (PKD NHS),3 a prospective, international 30-site observa-
tional study, we aimed to compare demographics, complications, and
laboratory results between two groups of patients with PK deficiency,
defined by their clinical severity. All participants in the PKD NHS had
molecularly confirmed PK deficiency and only splenectomized patients
were included in this analysis. Regular transfusions were defined as ≥6
discrete red cell transfusion episodes per year. Transfusion frequency
was observed over a 3-year period (divided into three 1-year periods)
post-splenectomy. Patients were categorized into two groups based on
transfusion frequency and splenectomy status. The most severe PK
deficiency phenotype group was defined as one that received regular
transfusions post-splenectomy. The comparison PK deficiency group
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did not receive regular transfusions post-splenectomy. Phenotype sta-
bility over the 3-year period was also assessed. Continuous parameters
were compared between the two groups using the Wilcoxon rank-sum
test and binary parameters were compared using the Fisher's exact text.
Different genotype classifications between the two groups were com-
pared using the Cochran-Armitage test.
TABLE 1 Demographics, clinical characteristics, and laboratory characteristics of the most severe phenotype PK deficiency group versus the
comparison PK deficiency group (n = 154 splenectomized patients with PK deficiency)
Most severe PK deficiency
phenotype: Splenectomized
patients receiving regular
transfusions, N = 30
Comparison PK deficiency
group: Splenectomized
patients not receiving regular








Age at diagnosis (y) 29 0.7 (0-47.6) 117 0.2 (0-42.3) .2
Age at enrollment (y) 30 26.2 (1.4-58.5) 124 22.7 (0.3-60.4) .95
Gender 30 122 .013
Female 23 (77%) 63 (51%)
Male 7 (23%) 61 (49%)
Amish 30 1 (3%) 124 51 (41%) <.001
Splenectomy 30 30 (100%) 124 124 (100%) -
Age at splenectomy (y) 30 5 (1.6-25.8) 124 3.6 (0.4-37.8) .011
Median hemoglobin post-splenectomy (g/dL)b 29 8.6 (6.3-11.0) 122 8.8 (6.5-12.3) .3
Mean total bilirubin at enrollment (mg/dL)b 24 3.5 (1.3-11.0) 104 3.9 (1.0-17.6) .95
Median lactate dehydrogenase at enrollment (U/L) 17 283.5 (142-1043) 57 215 (144-1007) .2
Median absolute reticulocyte count (x106 cells/μL)b 17 1.2 (0-681) 56 0.8 (0.1-1274.6) .09
Pulmonary hypertension 30 3 (10%) 122 5 (4%) .2
Extramedullary hematopoiesis 29 3 (10%) 121 21 (17%) .6
Liver cirrhosis 30 2 (7%) 122 5 (4%) .6
Endocrinopathy
Growth hormone deficiency 30 1 (3%) 124 4 (3%) .999
Hypoparathyroidism 30 2 (7%) 124 2 (2%) .2
Hypogonadal hypogonadism 30 1 (3%) 124 1 (1%) .4
Thyroid disease 30 5 (17%) 122 7 (6%) .06
Diabetes 30 2 (7%) 124 2 (2%) .2
Bone fracture (any) 30 7 (23%) 124 27 (22%) .8
History of iron chelation 30 27 (90%) 124 52 (42%) <.001
Iron overload (defined by maximum ferritin
>1000 ng/mL (2247 pmol/L) and/or iron chelation)
30 28 (93%) 108 55 (51%) <.001
Total number of lifetime transfusions 29 77 (10-544) 121 15 (0-492) <.001
Normalized PK enzyme activityc (%) at enrollment 15 −50 (−123.3-117.6) 31 −48.5 (−201.6-56.6) .5
Genotype groupsd 29 72 .7
M/M 14 (48%) 37 (51%)
M/NM 8 (28%) 21 (29%)
NM/NM 7 (24%) 14 (19%)
Abbreviations: M, missense; NM, non-missense.
aSample sizes are those with known data for the given characteristic.
bPre-transfusion values.
cThe normalized PK activity was calculated as: [(PKobs - PKLL) × 100]/(PKUL - PKLL) where PKobs is the observed PK enzyme value, and PKLL and PKUL are
the lower and upper limits of the reference range, respectively.
dAnalysis excluded Amish patients.
eUsing Wilcoxon rank-sum test for continuous parameters, Fisher's exact test for binary parameters, and Cochran-Armitage Trend Test for the genotype
groups comparison.
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Of the 255 patients enrolled in the PKD NHS, 154 splenectomized
patients were included in this analysis (30 patients in the most severe
PK deficiency phenotype group and 124 patients in the comparison PK
deficiency group). Patients in the most severe PK deficiency phenotype
group were followed in 21 of the 30 participating centers. Results of
the analysis comparing the two groups are described in Table 1. Given
our definition of disease-severity, the most severely affected patients
were more likely to have iron overload (93% vs 51%, P < .001), have
received chelation therapy (90% vs 42%, P < .001), and have had more
lifetime transfusions (median: 77 vs 15, P < .001) than the comparison
PK deficiency group. The most severe patients were more likely to be
female (77% vs 51%, P = .013) and older at the time of splenectomy
(median age: 5 vs 3.6, P = .011). Rates of other PK deficiency complica-
tions including pulmonary hypertension, extramedullary hematopoiesis,
liver cirrhosis, endocrinopathy, and bone fracture appeared similar
between the two groups. Laboratory values, including hemoglobin, total
bilirubin, normalized PK enzyme activity, and median absolute reticulo-
cyte count appeared similar between the two groups. In a second
analysis comparing the two groups, but with exclusion of the Amish
population (N = 52), findings were unchanged except that the age of
splenectomy was no longer significantly different (median: 5.1 vs
4.9 years, P = .96) between the most severe vs comparator PK defi-
ciency group. The underlying genetic mutation patterns (missense
mutations vs non-missense, such as frameshift variants or deletions)
also appeared similar between the groups. Phenotype over time was
fairly stable for patients who met the criteria for the comparator group
at the time of enrollment, but variable for patients who met the criteria
for most severe at enrollment, year 1, or year 2 (Table S1). Many of the
latter patients alternated severity level from year-to-year; just six (27%)
of the 22 patients who were most severe at any time point met the
definition of most severe at all three time points.
In summary, splenectomized patients with PK deficiency who are
not regularly transfused appear to have similar rates of PK deficiency-
associated complications (except for iron overload), and similar relevant
laboratory values and genotypes when compared to those who are reg-
ularly transfused. If severe hemolysis results in higher rates of PK defi-
ciency complications and hemolysis severity drives transfusion
frequency, the findings of this study are counterintuitive, in that iron
overload (and associated chelation therapy, an expected complication
of transfusions) was the only PK deficiency complication more common
in the most severe phenotype group. The similarity observed between
the most severe phenotype patients and comparison PK deficiency
patients could result from a protective effect of transfusion, as has been
described in thalassemia intermedia.7 It could also suggest transfusion-
dependence does not truly reflect disease severity, but is reflective of
varying provider practices and/or patient symptoms. The latter hypoth-
esis is supported by the fact that many patients classified as severe at
baseline no longer met criteria for this classification one and 2 years
later, demonstrating that transfusion requirements in patients with PK
deficiency fluctuate significantly over time. Transfusion-
dependence, therefore, does not necessarily imply a worse clinical out-
come in PK deficiency. Furthermore, there are no transfusion guidelines
for PK deficiency to help determine a universal transfusion threshold.
Early in life, transfusion requirements often decrease with age likely due
to fewer infection-associated hemolytic episodes, timing of splenec-
tomy, and age-differences in tolerance of anemia. The opposite is some-
times seen later in life, with transfusion requirements increasing during
middle-age, possibly due to physiologic age-related decline in cardiopul-
monary fitness. Physiologic determinants of severity of disease in PK
deficiency likely significantly relate to intrinsic red cell factors, such as
PK protein levels8 or non-PKLR red cell gene variants, of which transfu-
sion requirements may be a poor surrogate.
Our analysis is limited by the lack of a standard threshold in patients
with PK deficiency for the number of transfusions per year that meet
criteria for regularly transfused. Use of a stricter definition (≥7 transfu-
sions per year) would have significantly diminished the small sample size
making comparisons between the two groups difficult, and likely dimin-
ished the relevance of the analysis as it would be defining a rather niche
group in an already rare disease. Furthermore, the indication and goals
for initiating (and discontinuing) regular transfusions, for example to treat
a complication or improve subjective symptoms, were not collected.
In conclusion, the most severely affected patients with PK defi-
ciency defined as a requirement for regular RBC transfusions follow-
ing splenectomy have a similarly high rate of disease complications
and laboratory abnormalities as splenectomized patients not requiring
regular transfusions, with the exception of higher rates of iron
overload. Transfusion requirements seem to fluctuate considerably
over time and are not a valid marker of disease severity in PK
deficiency. A prospective study of a universal transfusion protocol
may be useful in understanding the role of transfusions in the man-
agement of patients with PK deficiency.
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low to moderate risk invasive
procedures
To the Editor:
Desmopressin (DDAVP), an analogue of vasopressin, has a been used
for management of coagulation disorders for about four decades. The
standard intravenous dose of DDAVP is 0.3 μg/kg of body weight,
which is interestingly based on a study in five healthy controls.1 This
dose was found to produce a maximal response with no further
increase in factor VIII activity (F VIII:C) levels at higher doses. The
maximum dose in United States is often capped at 25 to 30 μg in
obese patients.2 Though infrequent, desmopressin has been associ-
ated with undesirable side effects including hyponatremia, thrombo-
sis, headache and flushing.3 Given the reported side effects as well as
potentially higher risk of thrombosis in patients with normal or high
von Willebrand factor (VWF) levels, the lower dose can theoretically
have fewer side effects.
Recently, a lower dose of DDAVP, that is, 0.15 μg/kg of body
weight has been reported in children with similar efficacy as the full
dose.4 However, there have been no studies reported in adults to the
best of our knowledge. We carried out a retrospective review of adult
patients with von Willebrand disease (VWD) with subsequent age-
related normalization of their VWF levels.5 And, in those with a plate-
let function disorder (PFD) or bleeding of unknown cause (BUC) with
an increased bleeding score who received half dose DDAVP (0.15 μg/
kg of body weight). Patients were eligible for half dose DDAVP if they
had a history of VWD with subsequently normal or elevated VWF
levels or a PFD (Bernard Soulier and Glanzman's thrombasthenia
excluded), or BUC which was defined as an increased bleeding score
with normal laboratory findings, despite extensive hemostasis testing.
The medical record was reviewed for demographic information, age,
weight, sex, family history, International Society of Thrombosis and
Hemostasis Bleeding Assessment Tool bleeding score (ISTH BAT),
VWF levels, reason for desmopressin, reason for dose reduction,
bleeding control and sodium levels.
The study was approved by our Institutional Review Board and all
patient data was de-identified. The efficacy of DDAVP was judged by
bleeding control which was categorized as excellent, good, poor or no
control. Excellent control was defined as hemostasis not clinically dif-
ferent from normal, good control as mildly abnormal hemostasis, for
example slight oozing; poor control as moderate controllable bleeding,
while no control was defined as severe hemorrhage that is difficult to
control. The safety was assessed in terms of thrombosis, hypotension
and hyponatremia; classified as mild, moderate and severe. Mild hyp-
onatremia was defined as sodium levels of 130 to 134 mmol/L, mod-
erate hyponatremia as Na of 125 to 129 mmol/L and severe
hyponatremia as Na less than 125 mmol/L.
We identified 17 patients at our treatment center who received
half dose DDAVP for a total of 33 procedures (baseline characteristics
in Table S1). Among them, 82% were female with mean age of
50 years (range 18-71 years) and mean ISTH BAT score of 8.2 ± 3.7
(median score 7, range 4-17). So, 41.2% had either history of mild
VWD or history of low VWF levels, 29.4% patients had PFD, 23.5%
had BUC and only one patient (5.9%) had low VWF. The dose was
capped in two out of 17 patients at 12 μg for weight more than 80 kg.
These patients underwent a variety of procedures including upper/
lower endoscopies with biopsy or device placement (12.1%), thera-
peutic and diagnostic laparoscopies (9.1%); genitourinary (21.2%),
orthopedic (24.2%), dental (15.2%), ENT (9.1%) and miscellaneous pro-
cedures (9.1%). Twelve percent of these procedures were considered
high risk, which included tonsillectomy, hip replacement, shoulder
repair and bilateral mastectomy. Five patients had post-DDAVP levels
assayed; mean levels of factor VIII coagulant activity (FVIII:C) were
164.6 ± 39.6, VWF: ristocetin cofactor assay (VWF:RCo) 107.8 ± 28.8
and VWF Antigen (VWF:Ag) 108.7 ± 16.7. Twelve patients received
pre-operative and post-operative prophylaxis with either tranexamic
acid or aminocaproic acid if the procedure was mucosal based. Bleed-
ing control was excellent in 87.9% and good in 12.1% of procedures
(Table 1). Among non-bleeding complications, hyponatremia occurred
in 15.2% of procedures-there were two cases of mild and three of
moderate hyponatremia. None of them were symptomatic. One
patient had an episode of pre-syncope which was attributed to
DDAVP use. There were no thrombotic complications (Table 1).
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